ARTHEx Biotech Stock

AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.

Sign up today and learn more about ARTHEx Biotech Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About ARTHEx Biotech Stock

ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.

Funding History

January 2020$1.5M
June 2020$1.2M
July 2020$4.3M
October 2022$11.5M
October 2022$2.5M
May 2023$42.0M

Management

CEO, Co-founder

Beatriz Llamusí

Board Member

Albert Ferrer

Advisor and Co-founder

Rubén Artero

Board Member

Alain Huriez

Board Member

Lluis Pareras

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo